Showing posts with label pharmaceutical. Show all posts
Showing posts with label pharmaceutical. Show all posts

July 28, 2023

Transitioning from AI Gee-Whiz to B2B Results

We at CarePrecise are as fascinated as anyone about the miraculous capabilities -- and astounding failures -- of the new Large Language Model Artificial Intelligence tools now battling it out in cyberspace. But we've been around too long not to reserve some skepticism about the hype cycle. The other day I was chatting with an LLM about a new medical device. It initially pointed me to the manufacturer's site and some related promo material, but when I told it I'd rather read content from actual users of the equipment it suggested some sites I generally prefer not to use. When I asked instead for Facebook Groups, it gave me a list of suggestions with very specific Group names.

None of which turned out to exist.

So, when pressed for different information than it had been providing, my chatty AI tool employed a very human tactic: MSU.

This suggests to us that perhaps the best way to effectively use AI will be to point it to data you know is good -- specifically, your own data about your customers and prospects.

This approach is already taking root in pharmaceutical marketing. Directing AI tools toward rich, highly accurate reference data will, we think, become a key component in making the new technology produce credible, and actionable, results.

April 24, 2012

Hurry Up, Sunshine


Senators Chuck Grassly (R-IA) and Herb Kohl (D-WI), authors of the Physician Payments Sunshine Act, are pushing for CMS to get its final implementation rule out the door. Once the rule is published, the process of collecting data on financial transactions between doctors and industry vendors can start. Six months after CMS missed the October 1, 2011 statutory deadline, the senators expressed their displeasure with the agency's slow movement.

After missing the implementation date, CMS again missed a March 31, 2012 start date for the 1,150+ drug, device, biologics and medical supplies manufacturers to report all "transfers of value" given to physicians and teaching hospitals.

The Sunshine Act, as it is nicknamed, is designed to bring transparency to physician interactions with revenue sources that may unduly influence decisions regarding patient care. While such sources as manufacturers' payments for research are vital to healthcare technology development, patients should know when (and what for) large sums of money are attached to their doctors' treatment decisions.

Proposed implementation, published December 19, is available online.